next-gen chemo posit replac doxil
expand market initi outperform pt
initi coverag moleculin biotech outperform rate
price target base preclin clinic data suggest annamycin may
offer stepwis improv cardiotox vs anthracyclin emerg
data suggest differenti tissu penetr doxil doxorubicin
expect data present confer potenti support futur
develop solid tumor unrespons anthracyclin specif
annamycin demonstr accumul healthi malign lung tissu
believ compound may suitabl use advanc solid tumor patient
lung metastas forecast peak sale annamycin assum
market penetr compar current market share doxil
cardiotox limit use anthracyclin drug class associ
acut chronic cardiotox clinic profil anthracycline-
induc cardiotox well-docu cellular molecular process
well understood absenc known mechan anthracycline-
induc cardiotox believ safeti profil compound class
need evalu clinic trial
clean cardiotox profil annamycin moa cardiotox
anthracyclin well valid mbrx hypothes invers
flip physic posit hydroxl group oh
posit reduc cardiotox six clinic trial enrol total patient
report case cardiotox
annamycin sale model segment revenu us
rest world ex-u repres total expect annamycin
captur address us market row base use
patient current receiv doxil liposom doxorubicin product mbrx
recogn sale gross sale
tissu penetr expand market lung met intrigu data
suggest differenti tissu penetr annamycin includ accumul
lung view data corpor present pend adequ
draw conclus clinic relev hope learn
find futur medic meet potenti end
simplif unlock sharehold valu consid busi develop
core expertis mbrx furthermor pipelin seem broad
adequ fund mbrx believ simplif
pipelin priorit natur program attrit outlicens like surfac
year price histori mbrx
three program focus oncolog
includ annamycin may offer
better cardiotox profil
analyst certif import disclosur see disclosur
believ annamycin potenti offer clinic
import benefit doxil anthracyclin base
improv cardiotox structur differ may
assum annamycin uptak driven improv toler
potenti upsid drug demonstr clinic
relev anti-tumor activ base either longer durat
treatment differenti tissu accumul result
activ tumor type anthracyclin tradit
activ includ econom
forecast inhibitor phase clinic
develop gbm enter clinic develop
base differenti
md relationship extend forese futur
maintain access oncolog kol
revenu contribut pipelin program
annamycin
present medic meet data annamycin tissu
top-lin data phase i/ii studi topic inhibitor
ctcl
addit dose-escal data phase i/ii annamycin
studi aml patient
interim data phase studi inhibitor
phase ii aml data confirm cardiotox profil annamycin
adequ power studi
annamycin tissu distribut pattern result anti-tumor activ
solid tumor doxil activ includ lung metastasi
inhibitor demonstr anti-tumor activ one
solid tumor popul
improv access capit allow compani broaden clinic
develop program run company-fund studi
partner annamycin asia ex us region acceler
annamycin fail replic differenti cardiotox profil
discontinu md anderson relationship result loss access
import know-how potenti pipelin program
launch new target immuno-oncolog drug limit market
annamycin chemotherapi
annamycin pipelin program fail demonstr anti-
tumor activ clinic trial
annamycin demonstr meaning cardiotox clinic
trial still receiv box warn anthracyclin
price target base dcf analysi assum discount rate million share fulli dilut basi termin year
long-term growth rate
risk mbrx includ clinic trial failur annamycin phase i/ii aml studi studi inhibitor current
cash balanc suffici fund oper beyond repres novel target oncolog drug develop
amen direct regul clinic trial compound cardiotox safeti import potenti benefit
annamycin may need valid larg clinic trial chang physician behavior gain reimburs coverag much
compani portfolio may commerci partnership limit trade volum may exacerb share price volatil
mbrx may access addit capit accept term run busi beyond
note see mbrx stock trade specul appropri risk toler investor
initi outperform pt
initi coverag moleculin biotech inc outperform rate
price target base preclin clinic data suggest annamycin may offer
stepwis improv cardiotox compar anthracyclin emerg
data suggest differenti tissu penetr doxil doxorubicin
expect data present confer may support futur develop
solid tumor unrespons anthracyclin specif annamycin
demonstr accumul healthi malign lung tissu believ
compound may suitabl use advanc solid tumor patient lung
metastas forecast peak sale annamycin assum market
penetr compar current market share doxil
model call mbrx commerci annamycin us seek
partner market regard near-term news flow addit annamycin
preclin data expect mbrx present addit dose-escal safeti data
annamycin aml patient sefoulect phase ii dose middl
pt base dcf analysi assum discount rate million
share fulli dilut basi termin year revenu
cardiotox limit use anthracyclin
anthracyclin drug class associ acut chronic cardiotox
pericarditis/mycocard sudden cardiac death chronic effect includ declin left
ventricl function progress heart failur clinic profil
anthracycline-induc cardiotox well-docu cellular molecular
process well understood absenc known mechan anthracycline-
induc cardiotox view safeti profil compound class
need evalu clinic trial
annamycin four structur chang compar doxorubicin includ hydroxyl
group oh posit instead amino group demethoxyl
posit aglycon portion addit iodin group
posit invers flip physic posit
hydroxl group oh posit six clinic trial enrol total patient
report case cardiotox mbrx note three patient
dose-limit toxic dlt mg patient heavili pre-treat
fail induct treatment none dlt relat
furthermor due anthracyclin hydrophob mark affin lipid
membran numer studi demonstr liposom effici drug
deliveri vehicl result enhanc local tumor tissu mitig off-target
toxic wide use doxorubicin formul includ doxil use liposom
deliveri preclin model suggest similar benefit compar free annamycin
liposom formul product develop mbrx
forecast call annamycin launch us europ
model segment revenu us rest world row ex-u
repres sale base larger address market expect
annamycin captur address us market row base
use patient current receiv doxil liposom doxorubicin product could
upsid estim drug demonstr anti-tumor activ popul
respond anthracyclin outsid us forecast call annamycin
sold partner mbrx recogn tier royalti gross sale
expect mbrx recogn sale gross sale
upsid lung met respond anthracyclin
corpor present past year mbrx disclos limit preclin data
annamycin tissu accumul lung organ tissu exposur
clinic activ doxorubicin poor intrigu lung tissu
accumul view data corpor present primarili surviv data
mous model adequ draw conclus clinic relev hope learn
find futur medic meet potenti end
remain guard claim see data medic meet better
understand whether annamycin uptak malign lung tissu pronounc
vitro lung tissu cell line howev data support clinic develop
could multipl path upsid outlook base opportun greater
price flexibl base superior efficaci claim stronger competit barrier entri
method use patent use solid tumor respond
anthracyclin larger address market commerci uptak indic
anthracyclin use
simplif unlock sharehold valu
view busi develop core expertis mbrx manag expect
transact remain import part busi model furthermor view
compani pipelin broad adequ fund mbrx corpor
structur includ eu-bas develop vehicl complex
biotech investor accustom analyz view simplif
pipelin priorit natur program attrit outlicens like unlock
sharehold valu streamlin investor focu highest valu opportun
prioriti program receiv better fund
valuat share mbrx base sole potenti annamycin
use patient current candid receiv doxil gener equival
believ inhibitor glucos regul pathway
associ biolog valid target oncolog drug develop
target sourc multipl clinical-tri failur agent look
forward learn potenti differenti mbrx strategi
revisit assumpt compound
price target share mbrx base discount cash flow dcf
model sale annamycin aml breast cancer indic
anthracyclin standard care patient includ contribut
pipelin program revenu forecast
model call compani maintain us commerci right annamycin
receiv tier royalti sale region expect compani
achiev profit begin pay tax effect tax rate
forecast call peak annamycin sale termin year
revenu ex-u sale final year dcf valuat forecast free cash
flow driven global annamycin sale appli discount rate long-
term revenu growth rate fulli dilut share count million
oppenheim co inc estim compani document
view discount rate basi point lower typic
discount rate compani lead program phase clinic trial appropri
given valid anthracyclin potent class chemotherapi meaning
clinic safeti databas demonstr potenti cardiotox benefit annamycin
drug class partial off-set outlook anthracyclin competit
altern therapeut modal may treat similar patient popul without need
chemotherapi mbrx limit balanc sheet flexibl base current cash
balanc fund busi less month
long-term revenu growth rate line standard long-term biotech
growth rate base potenti annamycin use rang potenti tumor
type potenti upsid mbrx pipelin program
model call cash balanc fund oper increment capit
requir achiev profit
discount revenu dilut share incom work free cash growth cash moleculin biotech
outperform rate base primarili potenti annamycin demonstr
improv cardiotox profil compar doxil liposom doxorubicin
anthracyclin potenti differenti tissu penetr support use solid
tumor previous respond anthracyclin focus primarili
near term event de-risk assumpt
oppenheim co inc estim compani document
corpor present past year mbrx present limit preclin
data annamycin tissu accumul lung organ tissu
exposur clinic activ doxorubicin poor intrigu lung tissu
accumul view data corpor present adequ draw
conclus clinic relev hope learn find futur
medic meet potenti end
specif would like see data medic meet describ accumul
healthi vs malign tissu assess potenti use annamycin treatment lung
metastas patient receiv salvag therapi
term de-risk annamycin safeti profil focus enrol larger
cohort patient gain comfort cardiotox profil cautious
optimist phase ii data aml patient potenti significantli de-risk
toler profil serv import catalyst mbrx share
last attract target drug develop believ top-lin result
phase i/ii cohort cutan t-cell lymphoma ctlc patient treat
topic compound may support futur partner discuss
corpor histori busi model
moleculin product acquisit respect still oper two divis
within singl corpor structur includ separ chief medic offic annamycin
metabol program
current compani form combin moleculin juli
moleculin llc held licens agreement md anderson cover
compound parallel merger licens right
annamycin annam inc secur grant fund support futur develop
program less year later june compani rais initi
public offer began trade ticker mbrx
take focu product licens allow mbrx move multipl program
clinic develop less fund truncat preclin
eventtim importancepresent medic meet annamycin data solid phase i/ii studi topic ctlc clinic trial develop annamycin solid phase ii studi annamycin treatment phase develop iv compound treatment pancreat ii data annamycin treatment data iv mbrx outperform
mbrx licens three core technolog base research md anderson cancer
center mdacc execut associ mdacc platform includ
c-myc includ metabolism/glycosyl
mbrx core expertis busi develop signific clinical-tri
infrastructur view expect partneringboth academ group
discoveri work eventu commerci partnersto import compon
futur valu creation
base current product profil view annamycin specialti pharmaceut
product valid mechan action differenti base patient
toler believ product like requir signific sale market
invest maxim return sharehold tradit
biotechnolog product novel cancer target high level clinic
develop risk believ differ busi model coexist
phase ii develop view mbrx eventu need choos one
take pipelin simplif may unlock sharehold valu current pipelin
broad compani access capit clinic develop infrastructur
see program progress either posit data support partner
neg data justifi discontinu expect pipelin narrow
anthracyclin list world organ model list essenti
medicin view like remain mainstay cancer treatment
least next decad particularli patient metastat diseas annamycin
mbrx lead drug candid design maintain anti-tumor activ
anthracyclin class structur chang intend minim cardiotox
limit use compound class
structur four commonli use anthracyclinesdoxorubicin daunorubicin
doxorubicin deriv epirubicin idarubicin epirubicin deriv present
exhibit epirubicin deriv doxorubicin increas volum
distribut longer half-lif idarubicin deriv daunorubicin
lipophil higher cellular uptak daunorubicin
exhibit structur four common anthracyclin
mcgowan et al anthracyclin chemotherapi cardiotox cardiovascular drug therapi
limit understand cardiotox mechan
review dhingra et al publish januari issu cardio-oncolog
author distinguish acut chronic cardiotox effect induc
pericarditis/mycocard sudden cardiac death chronic effect includ declin left
ventricl function progress heart failur
clinic profil anthracycline-induc cardiotox well-docu
cellular molecular process well understood appar consensu
cardiotox like due multipl signal interact exhibit highlight
signal pathway implic anthracycline-induc cardiotox
take absenc known mechan anthracycline-induc cardiotox
necessit clinic valid safeti profil compound class
exhibit signal pathway implic anthracycline-induc cardiotox
dhingra et al chapter molecular mechan underli anthracyclin cardiotox challeng cardio-oncolog cardio-oncolog
differenti chemic structur annamycin limit cardiotox
describ antitumor activ free liposome-entrap anamycin
lipophil anthracyclin antibiot non-cross-resist properti zou et al
cancer research annamycin four structur chang compar
doxorubicin chang includ hydroxyl group oh posit instead
amino group demethoxyl posit aglycon portion
addit iodin group posit invers
 flip physic posit hydroxl group oh
posit chang graphic repres exhibit
exhibit comparison annamycin structur anthracyclin
zou et al antitumor activ free liposome-entrap anamycin lipophil anthracyclin antibiot non-cross-resist
alter chemic structur anthracyclin improv attribut preced
describ earlier idarubicin daunarubicin deriv prior gener
anthracyclin exhibit summar hypothes benefit structur chang
incorpor annamycin structur
take given limit understand mechan action moa
anthracyline-induc cardiotox view whether invers
hydroxl group posit improv advers event profil
exhibit benefit chemic structur chang
zou et al antitumor activ free liposome-entrap annamycin lipophil anthracyclin antibiot non-cross resit
due anthracyclin hydrophob mark affin lipid membran numer
studi demonstr liposom effici drug deliveri vehicl result
enhanc local tumor tissu mitig off-target toxic wide
model suggest similar benefit compar free annamycin liposom formul
product develop mbrx
annamycin potent resist sensit cell line
damag cell dna induc apoptosi anthracyclin must allow
accumul leukem cell suffici enter cell nucleu target cell
develop resist anthracyclin howev specif describ ling et al
paper in-vitro cytox cellular pharmacolog dna lesion induc
annamycin anthracylcyclin deriv high affin lipid membran
publish cancer research anthracyclin expel p-
addit amino group doxorubicin idarubicin chemotherapeut agent
result affin neg charg phospholipid make compound
suscept p-glycoprotein pump-medi drug resist exhibit show simplifi
mechan action associ resist
chemic structur chang purport benefit addit hydroxyl group oh positionparti offset cross-resist without alter interact topoisomeras ii reduc cardiotoxixitydemethoxyl posit aglycon portionincreas lipohil potenc addit iodin group posit hydroxl group oh positionincreas lipophil affin lipid membran stabil glycosid bondreduc cardiotox mbrx outperform
exhibit p-gp mediat efflux associ anthracyclin resist
mbrx complet preclin studi suggest hypothes resist benefit
compar doxorubicin confirm vitro cell line shown exhibit
take focu activ doxorubicin-resist cell line primari
driver product differenti due difficulti character benefit rel small
exhibit annamycin demonstr activ cell line resist
cell line potenc data underpin previous publish studi suggest
higher drug retent level annamycin compar doxorubicin doxorubicin-
sensit -resist leukemia cell exhibit
exhibit annamycin better tissu retent
ling et al vitro cytox cellular pharmacolog dna lesion induc annamycin anthracyclin deriv high affin
favor cardiotox profil patient
annamycin evalu six clinic trial enrol total patient without
report cardiotox mbrx note three patient dose-limit toxic
dlt mg patient heavili pre-treat fail
induct treatment none dlt relat cardiotox
phase i/ii trial nanomolecular liposom annamycin adult patient
relapsed/refractori acut lymphoblast leukemia publish clinic lymphoma
myeloma leukemia advers event document exhibit
exhibit annamycin
wetzler et al phase i/ii trial nanomolecular liposom annamycin adult patient relapsed/refractori acut lymphoblast leukemia
on-going phase i/ii annamycin studi aml patient
mbrx current enrol phase i/ii studi adult relapsed/refractori aml
patient dose escal studi determin recommend phase dose singl
agent follow standard induct therapi
patient must who-classif patholog diagnosi eastern
cooper oncolog group ecog perform statu addit inclus
criteria includ bilirubin time upper limit normal uln unless due gilbert
transaminas sgpt alkalin phosphatas time uln unless due organ
involv adequ renal function
exclus criteria includ diagnosi acut promyelocyt leukemia prior
mediastin radiotherapi concomit therapi exclud prophylact treatment
patient receiv two-hour iv infus liposom annamycin daili
consecut day follow day studi drug one treatment cycl day
phase primari endpoint determin dlt secondari endpoint includ pk
determin area plasma concentrationtim curv auc annamycin
metabolit annamycinol addit anti-leukem activ monitor
measur base intern work group iwg respons criteria aml
fda provid framework studi cardiotox clinic trial
current standard assess cardiotox clinic electrocardiograph evalu
begin earli clinic develop notabl fda suggest new
readout ecg waveform potenti biomark comprehens vitro
proarrhythmia assay cipa risk predict tool detail cardiotox
measur provid fda guidanc industri document entitl
clinic evalu qt/qtc interv prolong proarrhythm potenti
intrigu activ lung met model
mbrx spoken qualit differenti tissu accumul profil
annamycin publish preclin data topic howev compani
present mbrx describ result lewi lung carcinoma model data
present exhibit suggest treatment doxorubicin provid littl benefit
result rapid death anim day comparison annamycin-
take lewi lung carcinoma data suggest potenti benefit annamycin
set doxorubicin activ howev want see relat lung drug
concentr data draw conclus
exhibit annamycin perform better doxorubicin lung cancer model
furthermor mbrx present slide suggest potenti differenti profil
annamycin reticulisarcoma model present data indic exhibit
exhibit comparison anti-tumor activ annamycin tumor type
summar exhibit number current market anthracyclin
gener brand number list indic share market
annual revenu discuss
evalu ltd oppenheim co inc estim
doxorubicin wide use anthracyclin also one oldest
present exhibit
exhibit anthracyclin launch date known patent expiri date
evalu ltd oppenheim co inc estim
current us market graphic repres exhibit us sun
phramaceut primari gener liposom doxorubicin hcl supplier
exhibit us sale top anthracyclin product segment product year
evalu ltd oppenheim co inc estim
exhibit summar chang market share top anthracyclin sold
world-wide
evalu ltd oppenheim co inc estim
particular observ doxil jnj brand doxorubicin hydrochlorid lost
half market share group gener liposom
doxorubicin hcl market share trend us mirror world-wide trend smaller scale
domin market share captur liposom
view chemotherapi market us countri bifurc
hospit choos formul base primarili drug price hospit
make prescrib decis base combin drug price cost manag
chemotherapy-rel morbid patient outcom view latter group
potenti market next-gener chemotherapi product annamycin
use commerci profil doxil liposom doxorubicin hcl proxi
defin next-gener anthracyclin address market annamycin doxil
gener product gain wide accept premium price gener
doxorubicin base increment potenc improv toler profil offer
liposom formul mention doxil still associ signific
furthermor view oncologist current prescrib doxil instead lower price
doxorubicin potenti earlier adopt annamycin
doxil sold single-us ml vial iv inject brand chemotherapi
agent abraxan ex us sale demand meaning higher sale us
due ex-u price pressur class brand cancer therapi
brand chemotherapi may price gener cost still small fraction
high price target therapi immune-oncolog therapi
seen exhibit show declin gener doxil red bar
brand doxil past five year
evalu ltd oppenheim co inc estim
effect price pressur gener reflect signific declin
doxil sale shown exhibit
trend use anthracyclin outsid us stabl
estim volum expect increas next five year base
aggress treatment cancer develop economi asia south america
spepcif would note ex-u sale doxil roughli flat versu
contrast us experi overal anthracyclin market growth roughli
flat recent year see exhibit way background figur includ suppli
shortag doxil
evalu ltd oppenheim co inc estim
total arriv address market annual us anthracyclin script
world-wide anthracyclin script
term price estim current retail price per script averag lower
us anthracyclin exhibit model call wider
spread annamycin base greater price flexibl brand product us
specif assum base price per script us per script
row price multipl current doxil retail price per script
forecast call annamycin launch us europ
model segment revenu us row row repres
sale base larger address market outsid us
model call captur address us market row
due like limit reimburs certain countri outsid us expect
product sold partner mbrx recogn tier royalti
expect mbrx recogn sale gross sale
mention view inhibitor glucos
regul associ biolog valid target oncolog drug
develop target sourc multipl clinical-tri failur
opportun target glucos regul
target
long compel anti-canc target review wingelhof et al
march journal leukemia entitl implic signal
gene regul chromatin remodel hematopoiet cancer offer
contemporari analysi biolog rational rational includ in-vitro
inhibit lead growth inhibit apoptosi mani human cancer model
inhibit signal lead apoptosi tumor cell
normal cell multipl oncologen pathway converg overview
cellular activ present exhibit
anthracyclin market modeltot us anthracyclin script chang anthracyclin number anthracyclin script script annamycin per increas annual annamycin anthracyclin market modeltot row anthracyclin script growth anthracyclin number anthracyclin script script per increas annual row sale annamycin revenu annamycin mbrx world-wide annamycin revenu annamycin revenu medicaid retail per prescription/ price report evalu estim mbrx outperform
wingelhof et al implic signal gene regul chromatin remodel hematopoiet cancer leukemia
howev multipl inhibitor fail clinic trial hematolog
solid tumor indic review wong et al august issu expert
opinion investig drug entitl inhibitor potenti
futur cancer therapi provid comprehens analysi recent studi failur
describ exhibit
exhibit canon inhibit challeng drug develop
wong et al inhibitor potenti futur cancer therapi expert opinion investig drug
mbrx develop inhibitor compani believ compound
may differenti compound base potenti immun regulatori
activ specif shown increas activ
inhibit activ believ stimul t-cell activ
paper publish intern journal oncolog cheng et al
highlight therapeut potenti novel sensit dox-resist
triple-neg breast cancer tnbc author show inhibit p-
decreas express c-myc lead reduct
cell popul restor cancer cell sensit doxorubicin exhibit
depict propos mechan re-sensit cancer cell
cheng et al signal circuit regul stemness-medi doxorubicin resist triple-neg breast cancer cell
inhibitori effect intern journal oncolog
taken togeth cheng et al observ novel signal circuit
recent abstract present meet shown
induc apoptosi pancreat ductal adenocarcinoma pdac cell line
studi recurr malign glioma
mbrx md anderson current enrol phase studi adult patient
confirm progress brain metastas melanoma recurrent/progress
protocol call patient enrol studi subject receiv
twice daili monday wednesday friday week cycl
diseas progress unaccept toxic
patient select studi need abl toler mri procedur meet
total bilirubin creatinin clearanc prothrombin time
criteria includ chemotherapy/radi therapi within week background regimen
includ drug enzymat effect
program ctcl
topic analog use molecul treatment
psoriasi current develop cutan t-cell lymphoma ctcl
expect updat on-going phase ii studi
take mbrx made limit disclosur studi design expect number
